

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Mark J. RATAIN *et al.*

Serial No.: 10/751,606

Filed: January 5, 2004

For: OPTIMIZATION OF CANCER
TREATMENT WITH IRINOTECAN

Group Art Unit: 1634

Examiner: Bausch, Sarae L.

Atty. Dkt. No.: ARCD:389US

Confirmation No.: 2944

CERTIFICATE OF ELECTRONIC TRANSMISSION

I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office via EFS-Web on the date below:

July 20, 2007

Date

Gina N. Shishima

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The required fee in the amount of \$180.00 in connection with the filing of this paper are being charged to a credit card through EFS-Web concurrently with this submission. The Commissioner is hereby authorized to deduct any underpayment of fees or any additional fees required under 37 C.F.R. §§ 1.16 to 1.21 in connection with the filing of this paper from Fulbright & Jaworski Deposit Account No.: 50-1212/ARCD:389US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Gina N. Shishima
Reg. No. 45,104
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: July 20, 2007

Form PTO-1449 (modified)		Atty. Docket No.: ARCD:389US	Serial No.: 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Mark J. RATAIN <i>et al.</i>	
		Filing Date: January 5, 2004	Group: 1634
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C222	"Prosecution history for 90/007,601," Reexamination of United States Patent Number 6,395,481
	C223	Cote <i>et al.</i> , "UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan," <i>Clin. Cancer Res.</i> , 13(11):3269-3275, 2007.
	C224	Falandry <i>et al.</i> , "Individual genotyping to optimize chemotherapy in metastatic colorectal cancer (MCRC): The COLOGEN trial," <i>J. Clin. Oncology</i> , 2007 ASCO Annual Meeting Proceedings Part 1, 25(18S):2510, 2007.
	C225	Innocenti <i>et al.</i> , "A genotype-directed phase I study of irinotecan in advanced cancer patients," <i>J. Clin. Oncology</i> , 2007 ASCO Annual Meeting Proceedings Part 1, 25(18S):2502, 2007.
	C226	Iyer <i>et al.</i> , "Glucuronidation of TAS-103: A Novel Anticancer Agent," <i>Proc. Am. Soc. Clin. Oncol.</i> , 17:187a, No. 722, 1998.
	C227	Owens and Ritter, "The novel bilirubin/phenol UDP-glucuronosyltransferase UGT1 gene locus: implications for multiple nonhemolytic familial hyperbilirubinemia phenotypes," <i>Pharmacogenetics</i> , 2:93-108, 1992.
	C228	Takahashi <i>et al.</i> , "The Role of Glucuronidation in 7-Ethyl-10-hydroxycamptothecin Resistance in vitro," <i>Jpn. J. Cancer Res.</i> , 88:1211-1217, 1997.
	C229	Utsugi <i>et al.</i> , "Antitumor Activity of a Novel Quinoline Derivative, TAS-103, with Inhibitory Effects on Topoisomerases I and II," <i>Jpn. J. Cancer Res.</i> , 88:992-1002, 1997.

25797494.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPPE609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.